Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Antibiotic I is a preclinical-stage small molecule antimicrobial being developed by Fedora Pharmaceuticals. It is characterized by its broad-spectrum antibacterial activity, aimed at addressing the global challenge of antimicrobial resistance (AMR). While specific molecular targets have not been publicly disclosed, the candidate is part of Fedora's pipeline focused on innovative anti-infectives, alongside their more advanced candidate, nacubactam.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Antibiotic I.